Evommune (EVMN) EPS (Weighted Average and Diluted) (2024 - 2026)
Evommune (EVMN) reported EPS (Weighted Average and Diluted) of -$0.64 for Q1 2026, up 93.25% year-over-year from -$0.33 in Q1 2025, and down 104.23% quarter-over-quarter from $15.14 in Q4 2025.
Evommune (EVMN) EPS (Weighted Average and Diluted) (2024 - 2026) Analysis & Trends
Evommune (EVMN) has 3 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.64 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.64, up 93.25% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.05 (changed N/A YoY), and the FY2025 annual result was -$11.22, up 75.23% from the prior year.
- EPS (Weighted Average and Diluted) fell to -$0.64 in Q1 2026 per EVMN's latest filing, from $15.14 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $15.14 in Q4 2025 and troughed at -$14.6 in Q4 2024.
- A 3-year average of -$4.69 and a median of -$8.78 in 2025 frame the typical range for EPS (Weighted Average and Diluted).
- On a YoY basis, EPS (Weighted Average and Diluted) climbed as much as 203.7% in 2025 and fell as far as 22.92% in 2025.
- A 3-year view of EPS (Weighted Average and Diluted) shows it stood at -$14.6 in 2024, then soared by 203.7% to $15.14 in 2025, then sank by 104.23% to -$0.64 in 2026.
- Business Quant data shows EVMN's EPS (Weighted Average and Diluted) at -$0.64 in Q1 2026, $15.14 in Q4 2025, and -$8.07 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Evommune | 695.29 Mn | 483.82 Mn | - | -0.64 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.64 |
| Dec 31, 2025 | 15.14 |
| Sep 30, 2025 | -8.07 |
| Mar 31, 2025 | -9.48 |
| Dec 31, 2024 | -14.60 |
| Sep 30, 2024 | -10.47 |